Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    11432892 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: Cytarabine;   Drug: Mitoxantrone;   Drug: Gemtuzumab Ozogamicin;   Drug: All-trans-Retinoid Acid
2 Completed CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
Condition: Leukemia
Interventions: Drug: chemotherapy;   Drug: gemtuzumab ozogamicin

Indicates status has not been verified in more than two years